Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (alliance)

Clicks: 2
ID: 333245
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #74 of 74 articles by views in jnci cancer spectrum

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction We sought to evaluate the associations of post-diagnostic consumption of flavonoids and flavonoid-rich foods with survival among patients with stage III colon cancer enrolled in a clinical trial. Methods We conducted a prospective observational study of 1625 patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 (Alliance) randomized adjuvant chemotherapy trial who completed a self-reported food frequency questionnaire within 6 weeks of and again 14-16 months post-randomization. Intakes of flavonoids overall and by subclasses (anthocyanidins, flavanones, flavan-3-ols, flavones, flavonols, isoflavones) were computed by multiplying the consumption frequency of each dietary item by the nutrient content of its respective specified portions. Multivariable analyses for the primary (disease-free survival [DFS]) and secondary (overall survival [OS]) endpoints were adjusted for sociodemographic, clinical, dietary, and lifestyle factors. Bonferroni corrections were applied for analyses of flavonoid subclasses and flavonoid-rich foods. Results Over median follow-up of 5.9 years, flavonoid consumption either overall or by subclasses was not significantly associated with survival outcomes, with a hazard ratio (HR) (95% confidence interval [CI]) of 1.01 (0.75-1.37) for DFS among those in the highest relative to lowest consumption quintiles of total flavonoids. Exploratory analyses of flavonoid-rich foods intake did not demonstrate significant associations with DFS or OS after Bonferroni correction. Conclusion Among resected stage III colon cancer patients who received standardized treatment and follow-up within a nationwide randomized clinical trial, consumption of flavonoids was not associated with survival outcomes. ClinicalTrials.gov identifier: NCT01150045
Reference Key
openalex_W7223107262 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Seohyuk Lee, Chao Ma, Qian Shi, Pankaj Kumar, Félix Couture, Philip J. Kuebler, Smitha Krishnamurthi, Benjamin R. Tan, Ardaman P. Shergill, Eileen Mary O'Reilly, Anthony Frank Shields, Jeffrey A. Meyerhardt
Journal jnci cancer spectrum
Year 2026
DOI
10.1093/jncics/pkag112
URL
https://academic.oup.com/jncics/advance-article-pdf/doi/10.1093/jncics/pkag112/72201461/pkag112.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.